AC
AMPH icon

Aristeia Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

Aristeia Capital’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33,835
Closed -$777K – 540
2025
Q2 		$777K Hold
33,835
– – 0.02% 180
2025
Q1 		$981K Sell
33,835
-9,400
-22% -$300K 0.02% 141
2024
Q4 		$1.61M Buy
+43,235
New +$1.98M 0.05% 124

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Aristeia Capital's AMPH Position: Q3 2025 in Review

Aristeia Capital sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2025, closing a stake of 33,835 shares — an estimated $777K sold.

Aristeia Capital first reported a position in AMPH in Q4 2024 and held it in 3 quarters. The position peaked at $1.61M in Q4 2024. 243 funds tracked by Wall St. Rank hold AMPH as of Q3 2025.

  • Aristeia Capital reported no remaining Amphastar Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Aristeia Capital sold 33,835 Amphastar Pharmaceuticals shares in Q3 2025, an estimated $777K.
  • Aristeia Capital first reported a position in Amphastar Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Aristeia Capital's Amphastar Pharmaceuticals position peaked at $1.61M in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2025.

Based on Aristeia Capital's 13F filing for Q3 2025, filed 14 Nov 2025.